-
www.innovations.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-143-fullreport.pdf
April 01, 2018 - Population – infants (29 days to 1 year) (specify age range): Yes; 29-364 days.
q.
-
www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-143-fullreport.pdf
April 01, 2018 - Population – infants (29 days to 1 year) (specify age range): Yes; 29-364 days.
q.
-
www.qualitymeasures.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-089-fullreport.pdf
January 30, 2017 - Population – infants (29 days to 1 year) (specify age range): No.
q.
-
www.healthcare411.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-088-fullreport.pdf
January 05, 2017 - Population – infants (29 days to 1 year) (specify age range): No.
q.
-
www.healthcare411.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-089-fullreport.pdf
January 30, 2017 - Population – infants (29 days to 1 year) (specify age range): No.
q.
-
www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-088-fullreport.pdf
January 05, 2017 - Population – infants (29 days to 1 year) (specify age range): No.
q.
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-088-fullreport.pdf
January 05, 2017 - Population – infants (29 days to 1 year) (specify age range): No.
q.
-
www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-089-fullreport.pdf
January 30, 2017 - Population – infants (29 days to 1 year) (specify age range): No.
q.
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-089-fullreport.pdf
January 30, 2017 - Population – infants (29 days to 1 year) (specify age range): No.
q.
-
www.qualitymeasures.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-088-fullreport.pdf
January 05, 2017 - Population – infants (29 days to 1 year) (specify age range): No.
q.
-
www.cahps.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-143-fullreport.pdf
April 01, 2018 - Population – infants (29 days to 1 year) (specify age range): Yes; 29-364 days.
q.
-
ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-089-fullreport.pdf
January 30, 2017 - Population – infants (29 days to 1 year) (specify age range): No.
q.
-
ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-088-fullreport.pdf
January 05, 2017 - Population – infants (29 days to 1 year) (specify age range): No.
q.
-
ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-143-fullreport.pdf
April 01, 2018 - Population – infants (29 days to 1 year) (specify age range): Yes; 29-364 days.
q.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-future-presentation-format_research.pdf
January 01, 2019 - systematic review and meta-analysis
2006 Lancet
16443611 Effect of hepatitis B immunisation in newborn infants
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/horizon-scan_research-protocol.pdf
December 01, 2011 - , Motility Disorders
12 Pregnancy, including preterm birth
Examples of subcategories: Premature Infants
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/horizon-scan_research-protocol.pdf
December 01, 2011 - , Motility Disorders
12 Pregnancy, including preterm birth
Examples of subcategories: Premature Infants
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/methods-future-presentation-format_research.pdf
January 01, 2019 - systematic review and meta-analysis
2006 Lancet
16443611 Effect of hepatitis B immunisation in newborn infants
-
www.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-143-fullreport.pdf
April 01, 2018 - Population – infants (29 days to 1 year) (specify age range): Yes; 29-364 days.
q.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/procalcitonin-future_research.pdf
August 01, 2014 - Specifically, how should PCT be
used in the febrile infant who
presents through the ER?